S431
Clinical - Gynaecological
ESTRO 2026
Biostatistics, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India. 3 Department of Radiotherapy,, Erasmus University Medical Centre, Rotterdam, Netherlands. 4 Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen- Nürnberg, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany. 5 Radiation Therapy Department, ICANS, Strasbourg, France. 6 Radiation Medicine Program, Princess Margaret Hospital, Toronto, Canada. 7 Department of Radiation Oncology, University of Toronto, Toronto, Canada. 8 Department of Medical Physics, Leeds Cancer Centre, St James University Hospital, Leeds, United Kingdom. 9 Department of Medical Physics, Arthur J. E. Child Comprehensive Cancer Centre, Calgary, Canada. 10 Department of Oncology,, Western University, London, Canada. 11 Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark. 12 Department of Medicine, Aarhus University Hospital, Aarhus, Denmark. 13 Comprehensive Cancer Centre, University of Vienna, Vienna, Austria Purpose/Objective: Recurrences within previously irradiated field poses a therapeutic challenge in patients with gynaecological cancers. Reirradiation (Re-RT) represents a non-surgical alternative, yet evidence on in-field control, adverse events, radiation dose response relationship, and prognostic factors is fragmented. This meta-analysis addresses these gaps. Material/Methods: MEDLINE, Embase, and ScienceDirect were searched for studies (2000–2025) reporting Re-RT outcomes. All Re-RT modalities and study designs were eligible. Two reviewers independently extracted data on Re-RT indication, techniques, doses, in-field control (IFC), progression-free survival (PFS), overall survival (OS), and adverse events. Two-year IFC was pooled using a random-effects model; other outcomes were summarized descriptively. All analyses were performed in
Conclusion: CHC shows progressive and prolonged courses, with measurable mortality risk. Adverse event persistence and recurrence highlight the need for extended follow-up, management within multidisciplinary teams and a dedicated adverse event scoringthat accounts for multiplicity and persistence of adverse events. References: Pötter R, Tanderup K, Schmid MP, et al. MRI- guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. The Lancet Oncology 2021; 22(4): 538-47. Keywords: Chronic hemorrhagic Cystitis, Longitudinal course Infield control after gynaecological reirradiation: Results from the ReCOG meta-analysis. Supriya Chopra 1 , Varsha Hande 1 , Myvishvi Kannan 2 , Remi A Nout 3 , Stefanie Corradini 4 , Georges Noel 5 , Monica Serban 6,7 , Anna Clark 8 , Shima Tari 9 , Donna Murrell 10 , Heidi S Ronde 11,12 , Alina Sturdza 13 , Kari Tanderup 11,12 1 Department of Radiation Oncology, ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Navi Mumbai, India. 2 Department of Proffered Paper 1665
Made with FlippingBook - Share PDF online